• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于评估头部光化性角化病严重程度的评分系统:光化性角化病面积和严重指数。

A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index.

机构信息

Centroderm Clinic, Wuppertal, Germany.

Faculty of Health, University Witten-Herdecke, Witten, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1295-1302. doi: 10.1111/jdv.14267. Epub 2017 May 3.

DOI:10.1111/jdv.14267
PMID:28401585
Abstract

BACKGROUND

Actinic keratosis (AK) severity is currently evaluated by subjective assessment of patients.

OBJECTIVES

To develop and perform an initial pilot validation of a new easy-to-use quantitative tool for assessing AK severity on the head.

METHODS

The actinic keratosis area and severity index (AKASI) for the head was developed based on a review of other severity scoring systems in dermatology, in particular the psoriasis area and severity index (PASI). Initial validation was performed by 13 physicians assessing AK severity in 18 AK patients and two controls using a physician global assessment (PGA) and AKASI. To determine an AKASI score, the head was divided into four regions (scalp, forehead, left/right cheek ear, chin and nose). In each region, the percentage of the area affected by AKs was estimated, and the severities of three clinical signs of AK were assessed: distribution, erythema and thickness.

RESULTS

There was a strong correlation between AKASI and PGA scores (Pearson correlation coefficient: 0.86). AKASI was able to discriminate between different PGA categories: mean (SD) AKASI increased from 2.88 (1.18) for 'light' to 5.33 (1.48) for 'moderate', 8.28 (1.89) for 'severe', and 8.73 (3.03) for 'very severe' PGA classification. The coefficient of variation for AKASI scores was low and relatively constant across all PGA categories.

CONCLUSIONS

Actinic keratosis area and severity index is proposed as a new quantitative tool for assessing AK severity on the head. It may be useful in the future evaluation of new AK treatments in clinical studies and the management of AK in daily practice.

摘要

背景

光化性角化病(AK)的严重程度目前通过患者的主观评估进行评估。

目的

开发并初步验证一种新的用于评估头部 AK 严重程度的简单易用的定量工具。

方法

头部光化性角化病面积和严重指数(AKASI)是基于对皮肤科其他严重程度评分系统的回顾而制定的,特别是银屑病面积和严重程度指数(PASI)。最初的验证是由 13 名医生对 18 名 AK 患者和 2 名对照者进行的,使用医生整体评估(PGA)和 AKASI 评估 AK 严重程度。为了确定 AKASI 评分,将头部分为四个区域(头皮、额头、左右脸颊耳朵、下巴和鼻子)。在每个区域,估计受 AK 影响的区域百分比,并评估 AK 的三种临床体征的严重程度:分布、红斑和厚度。

结果

AKASI 与 PGA 评分之间存在很强的相关性(Pearson 相关系数:0.86)。AKASI 能够区分不同的 PGA 类别:平均(SD)AKASI 从“轻度”的 2.88(1.18)增加到“中度”的 5.33(1.48),“重度”的 8.28(1.89),“非常严重”的 8.73(3.03)。AKASI 评分的变异系数较低,在所有 PGA 类别中相对稳定。

结论

光化性角化病面积和严重指数被提出作为一种新的评估头部 AK 严重程度的定量工具。它可能在未来的 AK 治疗临床研究评估和日常实践中 AK 的管理中有用。

相似文献

1
A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index.一种用于评估头部光化性角化病严重程度的评分系统:光化性角化病面积和严重指数。
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1295-1302. doi: 10.1111/jdv.14267. Epub 2017 May 3.
2
Actinic keratosis area and severity index (AKASI) is associated with the incidence of squamous cell carcinoma.光化性角化病面积和严重指数(AKASI)与鳞状细胞癌的发生率相关。
J Eur Acad Dermatol Venereol. 2018 May;32(5):752-756. doi: 10.1111/jdv.14682. Epub 2017 Dec 18.
3
Daylight photodynamic therapy for severe facial and scalp actinic keratosis: a prospective non-sponsored single-centre study employing the actinic keratosis area and severity index (AKASI).日光光动力疗法治疗严重面部和头皮光化性角化病:一项采用光化性角化病面积和严重程度指数(AKASI)的前瞻性非赞助单中心研究。
Eur J Dermatol. 2019 Feb 1;29(1):67-74. doi: 10.1684/ejd.2018.3492.
4
Diclofenac Sodium 3% in Hyaluronic Acid 2.5% Gel Significantly Diminishes the Actinic Keratosis Area and Severity Index.双氯芬酸钠 3%联合透明质酸 2.5%凝胶显著减少光化性角化病面积和严重指数。
Skin Pharmacol Physiol. 2018;31(4):206-211. doi: 10.1159/000488248. Epub 2018 May 23.
5
Photodynamic therapy leads to significant improvement of actinic keratosis area and severity index (AKASI).光动力疗法可显著改善光化性角化病面积和严重指数(AKASI)。
Photodiagnosis Photodyn Ther. 2018 Mar;21:66-70. doi: 10.1016/j.pdpdt.2017.10.007. Epub 2017 Oct 16.
6
Comparison of Actinic Keratosis and Severity Index with Physician Global Assessment and Total Lesion Count and the Ability to Predict Skin Cancer.光化性角化病与严重程度指数与医生整体评估及总皮损计数的比较以及预测皮肤癌的能力。
Dermatol Pract Concept. 2022 Jan 1;12(1):e2022031. doi: 10.5826/dpc.1201a31. eCollection 2022 Feb.
7
Actinic keratosis area and severity index is not correlated with photodynamic therapy procedural pain.光化性角化病面积和严重程度指数与光动力治疗过程中的疼痛无关。
Photodiagnosis Photodyn Ther. 2020 Sep;31:101946. doi: 10.1016/j.pdpdt.2020.101946. Epub 2020 Aug 11.
8
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.一种用于评估光化性角化病疾病严重程度分级的新型光化性角化病皮损评估量表。
Acta Derm Venereol. 2017 Oct 2;97(9):1108-1113. doi: 10.2340/00015555-2710.
9
Actinic Keratosis Area Severity Index (AKASI): reproducibility study and comparison with total lesion count.光化性角化病面积严重程度指数(AKASI):再现性研究及与总病损数的比较
Br J Dermatol. 2018 Sep;179(3):763-764. doi: 10.1111/bjd.16559. Epub 2018 Jun 20.
10
Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study.1%替拉替尼软膏显著降低光化性角化病患者的光化性角化病面积和严重程度指数:一项真实世界研究的结果
J Clin Med. 2023 Jul 22;12(14):4837. doi: 10.3390/jcm12144837.

引用本文的文献

1
Effect of a Photolyase-Based Medical Device on Actinic Keratosis in Phototypes III-IV Patients: Real-Life Clinical Setting.一种基于光裂合酶的医疗设备对Ⅲ-Ⅳ型光皮肤患者光化性角化病的影响:真实临床环境
Dermatol Ther (Heidelb). 2025 Jun 16. doi: 10.1007/s13555-025-01455-6.
2
Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection.1%替拉替尼软膏干预治疗HIV感染者光化性角化病的缓解率
Diagnostics (Basel). 2025 Feb 7;15(4):401. doi: 10.3390/diagnostics15040401.
3
Self-Applied Daylight Photodynamic Therapy: A Paradigm Shift?
自我应用日光光动力疗法:一种范式转变?
Int J Mol Sci. 2025 Jan 13;26(2):628. doi: 10.3390/ijms26020628.
4
Actinic keratosis metrics.光化性角化病计量学。
Arch Dermatol Res. 2024 Aug 20;316(8):543. doi: 10.1007/s00403-024-03305-5.
5
Dynamic optical coherence tomography unveils subclinical, vascular differences across actinic keratosis grades I-III.动态光学相干断层扫描揭示了 I-III 级光化性角化病各等级的亚临床血管差异。
Exp Dermatol. 2024 Aug;33(8):e15153. doi: 10.1111/exd.15153.
6
Clinical and Dermoscopic Diagnosis of Actinic Keratosis.光化性角化病的临床与皮肤镜诊断
Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024147S. doi: 10.5826/dpc.1403S1a147S.
7
An Update on Non-Invasive Skin Imaging Techniques in Actinic Keratosis-A Narrative Review.光化性角化病的无创性皮肤成像技术更新:综述
Medicina (Kaunas). 2024 Jun 26;60(7):1043. doi: 10.3390/medicina60071043.
8
The Promise of Semantic Segmentation in Detecting Actinic Keratosis Using Clinical Photography in the Wild.在自然环境下使用临床摄影检测光化性角化病中语义分割的前景。
Cancers (Basel). 2023 Oct 5;15(19):4861. doi: 10.3390/cancers15194861.
9
Editorial: Non-invasive diagnostic tools in the management of skin disorders.社论:皮肤疾病管理中的非侵入性诊断工具
Front Med (Lausanne). 2023 Aug 31;10:1271195. doi: 10.3389/fmed.2023.1271195. eCollection 2023.
10
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.用于光化性角化病预防和治疗的药物制剂:综述。
Int J Mol Sci. 2023 Mar 5;24(5):4989. doi: 10.3390/ijms24054989.